VTRS · Viatris Inc.
$18.29
+1.61% last session
End-of-day data · close of 2026-10-26
Market cap
$21B
Enterprise value
$33B
Trailing P/E
—
Forward P/E
6.8
Dividend yield
3.0%
Beta
0.86
Avg volume
9M
Employees
30K
Daily Change %
1.61%
5 Days Change
-1.03%
10 Days Change
-1.98%
30 Days Change
2.58%
60 Days Change
11.93%
Month to Day Change
4.75%
Year to Day Change
50.37%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — VTRS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-26
Latest call per bank · past 12 months
JP Morgan
Neutral$20.00
+9.3% vs priceUBS
Buy$26.00
+42.2% vs priceBarclays
Overweight$22.00
+20.3% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-26 | Piper Sandler | Maintains | Neutral | $13.00 → $14.00 |
| 2026-10-21 | JP Morgan | Maintains | Neutral | $18.00 → $20.00 |
| 2026-10-05 | UBS | Maintains | Buy | $23.00 → $26.00 |
| 2026-09-23 | Oppenheimer | Initiates | Outperform | $0.00 → $25.00 |
| 2026-09-16 | Piper Sandler | Maintains | Neutral | $12.00 → $13.00 |
| 2026-09-09 | Leerink Partners | Initiates | Outperform | $0.00 → $20.00 |
| 2026-09-08 | Argus Research | Maintains | Buy | $15.00 → $20.00 |
| 2026-05-19 | Barclays | Maintains | Overweight | $17.00 → $22.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 58 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 6.2% above the 50-day MA ($17.22).
- bullish: Price vs 200-day MA: Trading 17.1% above the 200-day MA ($15.62).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.02) — short-term momentum is improving.
- bullish: 52-week range: Price is within 5% of the 52-week high ($18.66).
VTRS Price Chart
Loading chart for VTRS…
Fundamentals
About Viatris Inc.
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$65B 31.1% YTD
TEVA
Teva Pharmaceutical Industries
$47B 28.0% YTD
HLN
Haleon plc
$45B 2.9% YTD
ZTS
Zoetis Inc.
$33B -34.6% YTD
UTHR
United Therapeutics Corporation
$25B 21.7% YTD
NBIX
Neurocrine Biosciences, Inc.
$15B 2.9% YTD
ELAN
Elanco Animal Health Incorporat
$11B 1.5% YTD
RDY
Dr. Reddy's Laboratories Ltd
$11B -1.4% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.